La chaîne d'options affiche les données clés des options sur actions de Scinai Immunotherapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Scinai Immunotherapeutics..

Scinai Immunotherapeutics (NASDAQ:SCNI) Stock, Chaîne d'Options

Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics Ltd

Press Releases

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

Earnings

Scinai Announces Annual Financial Results for 2024

Small Cap

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

News

Contracts

Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities

SCNI

Apollomics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Azitra

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Bio Green Med Solution, Inc. - Common Stock

Bio Green Med Solution

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

GRI Bio

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Kala Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Oragenics

Onconetix

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Revolution Medicines

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Alaunos Therapeutics, Inc. - Common Stock

Comments

Scinai Immunotherapeutics

Scinai Immunotherapeutics (SCNI) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL